Jean Franchi Sells 353 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean Franchi sold 353 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $69.06, for a total value of $24,378.18. Following the completion of the sale, the chief financial officer directly owned 70,990 shares in the company, valued at approximately $4,902,569.40. The trade was a 0.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Disc Medicine Price Performance

Disc Medicine stock traded down $1.29 during mid-day trading on Friday, hitting $66.62. 345,062 shares of the company were exchanged, compared to its average volume of 762,160. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $99.50. The company has a market capitalization of $2.51 billion, a P/E ratio of -12.45 and a beta of 0.88. The business’s 50 day simple moving average is $74.70 and its two-hundred day simple moving average is $75.34. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) EPS for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. Analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on IRON shares. Stifel Nicolaus cut their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. BMO Capital Markets reduced their price target on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 17th. Wedbush decreased their price objective on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, January 21st. Finally, Morgan Stanley set a $75.00 target price on Disc Medicine in a research report on Tuesday, February 17th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its holdings in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock valued at $125,557,000 after acquiring an additional 828,248 shares during the last quarter. BVF Inc. IL acquired a new stake in Disc Medicine during the 4th quarter worth approximately $51,616,000. Jennison Associates LLC acquired a new stake in Disc Medicine during the 4th quarter worth approximately $42,252,000. Perceptive Advisors LLC purchased a new position in shares of Disc Medicine in the 4th quarter valued at $35,794,000. Finally, RA Capital Management L.P. raised its position in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after purchasing an additional 399,026 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.